[The use of pantogam in patients with moderate cognitive disorders of vascular genesis].
Forty-five patients with discirculatory encephalopathy, I-II stages, and moderate cognitive disorders of vascular genesis were examined. All patients were stratified into 2 groups: 25 patients of the main group received pantoham in the complex therapy in dose 250 mg 3 times a day during 2 months; 20 patients of the comparison group received only a unified therapy (antihypertensive drugs and, if necessary, coronarolytics and glucose-decreasing drugs. The clinical/neurological and instrumental examinations and neuropsychological testing were performed before the treatment and after 8 weeks. The subjective improvement of the state of patients treated with pantoham, together with the significant improvement (p < 0.05) in the performance of cognitive tests (a battery of frontal dysfunction tests, the Clock drawing test, generalization ability) was found. No positive changes in the performance of cognitive tests were observed in the comparison group. None of the patients had side-effects that led to a change of the therapeutic scheme.
Mikhaĭlova
N A
NA
Kamchatov
P R
PR
D000368:Aged; D002561:Cerebrovascular Disorders / Q000150:complications*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000627:therapeutic use*; D010205:Pantothenic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018697:Nootropic Agents; C016030:pantogab; D010205:Pantothenic Acid; D005680:gamma-Aminobutyric Acid